MENUMENU
  • About Us
    • Statement From CEO
    • Our Leadership
    • Partnerships
  • Programs
    • Cancer Immunotherapy
    • SARS-CoV-2 Vaccine
    • Publications
  • News & Media
  • Contact Us
    • Contact Us
    • Careers
MENUMENU
  • About Us
    • Statement From CEO
    • Our Leadership
    • Partnerships
  • Programs
    • Cancer Immunotherapy
    • SARS-CoV-2 Vaccine
    • Publications
  • News & Media
  • Contact Us
    • Contact Us
    • Careers
  •  
  • May 2017

AIVITA Appoints Operations and Customer Care Executive Ed Inal as Chief Operating Officer

AIVITA Biomedical to Feature Skin Care Technology at Upcoming Music City SCALE Symposium

AIVITA Biomedical is a biotechnology company developing personalized vaccines that target COVID-19 and the seed of all cancers using our autologous cell platform. We leverage our unique expertise in stem cell growth and directed, high-purity differentiation to develop safe, efficient and economical manufacturing processes for therapeutic development in cancer, infectious disease and other fields.

Recent News

  • AIVITA Biomedical Announces Case Report Suggesting Positive Collateral Benefits in Systemic Lupus Erythematosus Achieved Through the Use of Its Dendritic Cell Vaccine Kit
  • AIVITA Biomedical CEO Dr. Hans Keirstead to Deliver Keynote at Advanced Therapies Europe
  • AIVITA Biomedical CEO Dr. Hans Keirstead Awarded OC50 Honor by The Orange County Business Journal
  • AIVITA Biomedical CEO Dr. Hans Keirstead to Chair Keynote Panel and Present at World Vaccine Congress
  • AIVITA Biomedical CEO Dr. Hans Keirstead to Chair Keynote Panel and Present at World Vaccine Congress

Site Navigation

  • About Us
  • Programs
  • News & Media
  • Contact Us
Copyright © 2023 | AIVITA Biomedical, Inc.